🇪🇺 Tamiflu® in European Union

EMA authorised Tamiflu® on 20 June 2002

Marketing authorisation

EMA — authorised 20 June 2002

  • Application: EMEA/H/C/000402
  • Marketing authorisation holder: Roche Registration GmbH
  • Local brand name: Tamiflu
  • Indication: Treatment of influenza Tamiflu is indicated in adults and children including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.Prevention of influenza Post-exposure prevention in individuals one year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. The appropriate use of Tamiflu for prevention of influenza should be determined on a case-by-ca
  • Status: approved

Read official source →

Other Infectious Disease / Virology approved in European Union

Frequently asked questions

Is Tamiflu® approved in European Union?

Yes. EMA authorised it on 20 June 2002.

Who is the marketing authorisation holder for Tamiflu® in European Union?

Roche Registration GmbH holds the EU marketing authorisation.